Citations

Showing 10 of 108081 citations.

BLAST-AHF: insights into biased AT1 ligands and heart failure. Beginning of the end or end of the beginning?
Sugihara, Shinobu , Burnett, John C.

Mayo Clinic

European Heart Journal | May 8, 2017 | Volume: 38 | Issue: 30 | Pages: 2374-2376

10.1093/eurheartj/ehx276 | PMID 28575396 Get It

Acute and midterm results following perventricular device closure of muscular ventricular septal defects: A multicenter PICES investigation
Gray, Robert G. , Menon, Shaji C. , Johnson, Joyce T. , Bingler, Michael, Breinholt, John P. , Kenny, Damien , Lozier, John S. , Murphy, Joshua, Sathanandam, Shyam , Taggart, Nathaniel W. , Trucco, Sara M. , Goldstein, Bryan H. , Gordon, Brent M. , Armstrong, Aimee K. , Taggart, Nathaniel W , Goldstein, Bryan H

Mayo Clinic

Catheterization and Cardiovascular Interventions | May 8, 2017 | Volume: 90 | Issue: 2 | Pages: 281-289

10.1002/ccd.27121 | PMID 28805027 Get It

ObjectivesTo describe acute and mid‐term results of hybrid perventricular device closure of muscular ventricular septal defects (mVSDs).BackgroundPerventricular device closure of mVSDs can mitigate technical limitations of percutaneous closure and need for cardiopulmonary bypass or ventriculotomy with a surgical approach.MethodsThis is a multicenter retrospective cohort study of patients undergoing hybrid perventricular mVSD device closure from 1/2004 to 1/2014. Procedural details, adverse events, outcomes, and follow‐up data were collected. Patients were divided into two groups: (1) simple (mVSD closure alone) and (2) complex (mVSD closure with concomitant cardiac surgery).ResultsForty‐seven patients (60% female) underwent perventricular mVSD device closure at a median age of 5.2 months (IQR 1.8–8.9) and weight of 5.1 kg (IQR 4.0–6.9). Procedural success was 91% [100% (n = 22) simple and 84% (n = 21/25) complex]. Adverse events occurred in 19% (9/47) [9% (2/22) simple and 28% (7/25) complex]. Hospital length of stay (LOS) was shorter in the simple vs. complex group (4 vs. 14 days, P < 0.01). At mid‐term follow‐up of 19.2 months (IQR 2.3–43) 90% of pts had complete mVSD closure; none developed late heart block, increased atrioventricular (AV) valve insufficiency or ventricular dysfunction.ConclusionsPerventricular device closure of simple mVSD was associated with a high rate of procedural success, few adverse events, and short hospital LOS. Procedural adverse events were associated with the presence of concomitant complex surgery. Residual mVSD, AV valve insufficiency, or ventricular dysfunction were uncommon at mid‐term follow‐up. © 2017 Wiley Periodicals, Inc.
Comparison of the hospital costs for two-stage reimplantation for deep infection, single-stage revision and primary total elbow arthroplasty
Wagner, Eric R. , Ransom, Jeanine E. , Kremers, Hilal Maradit , Morrey, Mark, Sanchez-Sotelo, Joaquin, Morrey, Mark E. , Sánchez‐Sotelo, Joaquín , Wagner, Eric R , Maradit Kremers, Hilal

Mayo Clinic

Shoulder & Elbow | May 8, 2017 | Volume: 9 | Issue: 4 | Pages: 279-284

10.1177/1758573217706364 | PMID 28932285 Get It

Background The purpose of the present study was to determine the cost of two-stage reimplantation for the treatment of deep infection after total elbow arthroplasty (TEA) and compare this with primary and aseptic revision TEA. Methods Three hundred and seventy-one primary TEA and 286 revision TEAs (including 47 elbows requiring two-stage reimplantation) were performed. Total direct medical costs during each hospitalization were obtained from our institutional research database and compared for three groups: primary TEA, revision for nonseptic reasons and two-stage reimplantation for deep infection. Results The mean cost of an uncomplicated primary TEA and aseptic revision TEA was $18,464 and $18,796, respectively. The mean overall cost associated with two-stage reimplantation increased to $34,286. Two-stage reimplantation increased both Part A (hospital costs) and Part B (professional costs). The mean Part A cost for septic revision TEA was $29,102 versus $15,844 for primary TEA. The mean Part B cost for septic revision TEA was $5,184 versus $2,621 for primary TEA. Conclusions Two-stage reimplantation for treatment of an infected TEA costs 186% the hospital cost of a primary uncomplicated or aseptic revision TEA. The overall cost to society is even greater if we take into account the cost of antibiotic therapy in between stages and lost days from work.
Mapping and comparing bacterial microbiota in the sinonasal cavity of healthy, allergic rhinitis, and chronic rhinosinusitis subjects
Delisle, Josie, Barker, Bridget M. , Rank, Matthew A. , Schupp, James M., Gillece, John D. , Cope, Emily K. , Chia, Nicholas , Lal, Devyani , Keim, Paul , Chia, Nicholas

Mayo Clinic

International Forum of Allergy & Rhinology | May 8, 2017 | Volume: 7 | Issue: 6 | Pages: 561-569

10.1002/alr.21934 | PMID 28481057 Get It

Background The role of microbiota in sinonasal inflammation can be further understood by targeted sampling of healthy and diseased subjects. We compared the microbiota of the middle meatus (MM) and inferior meatus (IM) in healthy, allergic rhinitis (AR), and chronic rhinosinusitis (CRS) subjects to characterize intrasubject, intersubject, and intergroup differences. Methods Subjects were recruited in the office, and characterized into healthy, AR, and CRS groups. Endoscopically‐guided swab samples were obtained from the MM and IM bilaterally. Bacterial microbiota were characterized by sequencing the V3‐V4 region of the 16S ribosomal RNA (rRNA) gene. Results Intersubject microbiome analyses were conducted in 65 subjects: 8 healthy, 11 AR, and 46 CRS (25 CRS with nasal polyps [CRSwNP]; 21 CRS without nasal polyps [CRSsNP]). Intrasubject analyses were conducted for 48 individuals (4 controls, 11 AR, 8 CRSwNP, and 15 CRSwNP). There was considerable intersubject microbiota variability, but intrasubject profiles were similar ( p = 0.001, nonparametric t test). Intrasubject bacterial diversity was significantly reduced in MM of CRSsNP subjects compared to IM samples ( p = 0.022, nonparametric t test). CRSsNP MM samples were enriched in Streptococcus , Haemophilus , and Fusobacterium spp. but exhibited loss of diversity compared to healthy, CRSwNP, and AR subject‐samples ( p < 0.05; nonparametric t test). CRSwNP patients were enriched in Staphylococcus , Alloiococcus , and Corynebacterium spp. Conclusion This study presents the sinonasal microbiome profile in one of the larger populations of non‐CRS and CRS subjects, and is the first office‐based cohort in the literature. In contrast to healthy, AR, and CRSwNP subjects, CRSsNP MM samples exhibited decreased microbiome diversity and anaerobic enrichment. CRSsNP MM samples had reduced diversity compared to same‐subject IM samples, a novel finding.
Quantitation of valve regurgitation severity by three‐dimensional vena contracta area is superior to flow convergence method of quantitation on transesophageal echocardiography
Abudiab, Muaz M. , Naqvi, Tasneem Z. , Liu, Shuang , Naqvi, Tasneem Z , Chao, Chieh‐Ju , Liu, Shuang

Mayo Clinic

Echocardiography | May 8, 2017 | Volume: 34 | Issue: 7 | Pages: 992-1001

10.1111/echo.13549 | PMID 28480555 Get It

BackgroundQuantitation of regurgitation severity using the proximal isovelocity acceleration (PISA) method to calculate effective regurgitant orifice (ERO) area has limitations. Measurement of three‐dimensional (3D) vena contracta area (VCA) accurately grades mitral regurgitation (MR) severity on transthoracic echocardiography (TTE).MethodsWe evaluated 3D VCA quantitation of regurgitant jet severity using 3D transesophageal echocardiography (TEE) in 110 native mitral, aortic, and tricuspid valves and six prosthetic valves in patients with at least mild valvular regurgitation. The ASE‐recommended integrative method comprising semiquantitative and quantitative assessment of valvular regurgitation was used as a reference method, including ERO area by 2D PISA for assigning severity of regurgitation grade.ResultsMean age was 62.2±14.4 years; 3D VCA quantitation was feasible in 91% regurgitant valves compared to 78% by the PISA method. When both methods were feasible and in the presence of a single regurgitant jet, 3D VCA and 2D PISA were similar in differentiating assigned severity (ANOVAP<.001). In valves with multiple jets, however, 3D VCA had a better correlation to assigned severity (ANOVAP<.0001). The agreement of 2D PISA and 3D VCA with the integrative method was 47% and 58% for moderate and 65% and 88% for severe regurgitation, respectively.ConclusionMeasurement of 3D VCA by TEE is superior to the 2D PISA method in determination of regurgitation severity in multiple native and prosthetic valves.
Trigger Point Injections for Pelvic Floor Myofascial Spasm Refractive to Primary Therapy
Fouad, Lina S., Pettit, Paul D. , Threadcraft, Marcus , Wells, Ali , Micallef, Audrey, Chen, Anita H. , Fouad, Lina

Mayo Clinic

Journal of Endometriosis and Pelvic Pain Disorders | May 7, 2017 | Volume: 9 | Issue: 2 | Pages: 125-130

10.5301/jeppd.5000283 Get It

Introduction A retrospective chart review was conducted of visual analog scale (VAS) scores completed before and after trigger point injections (TPIs) for pelvic floor myofascial spasm to evaluate response. Methods Sixty-eight female patients who underwent TPIs from October 9, 2007 to March 12, 2015 were included. The primary end point was the difference between scores. Secondary analyses were conducted for patients who needed repeat TPIs. Descriptive and paired t test analyses were used. Results The key result was an improvement in VAS scores for 65% (44/68) of patients (p<0.0001). The median pre-injection VAS score was 7 (1 to 10), (mean 6.3). The median post-injection VAS score was 4 (0 to 9), (mean 4.3). The median difference between scores in patients who improved was 3 (1 to 8), (mean 3.6). Seventeen of 68 (25%) patients needed repeat TPI, and the median time between injections was 1.5 months (1 to 7 months), (mean 2.2 months). When analyzing pre-injection VAS scores in patients who underwent subsequent repeat injection when compared to patients who did not require repeat injection, there was no difference (p = 0.32). In addition, the differences between pre- and post-injection VAS scores in the patients who underwent repeat injection and those who did not was not significant (p = 0.26). Conclusions We report on 68 women who underwent TPIs, with an improvement in VAS pain scores in 65%. It appears that TPIs for pelvic floor myofascial spasm are successful in reducing pain scores for patients who are refractory to primary therapy.
Obstetrics and Gynecology Fellowship Interview Preferences [22I]
Barnard, Emily, Byrnes, Jenifer N., Occhino, John A.

Mayo Clinic

Obstetrics & Gynecology | May 6, 2017 | Volume: 129 | Issue: 1 | Pages: 98S-98S

10.1097/01.aog.0000514961.42758.9a Get It

INTRODUCTION: The number of applicants to Obstetrics and Gynecology subspecialty fellowships is projected to increase; however, it is known that the interview process is taxing for both applicants and the programs they attend. Concerns include excessive time away from work, cost, lack of coordination for regional travel, and overlapping interview dates. Little is known about applicant preferences for interviewing. METHODS: An e-mail link to a survey designed using web-based tool SurveyMonkey was sent to all residency directors for distribution to fourth year residents at ACGME-accredited Obstetrics and Gynecology programs in the United States. RESULTS: A total of 190 residents responded, 138 of whom applied to fellowship in 2016. Applicants were predominantly female (73.6%), Caucasian (78.3%), married (76.7%), and without children (74.4%). Most (81.3%) were from an academic program. Applicants attended a mean of 10.9 interviews; the most common reason to cancel was conflict with another interview (72.3%). Saturday was the most preferred interview day (46.7%). The majority of applicants preferred half-day interviews (93.2%), and 61.0% preferred an 0800 start to earlier or later times. A pre-interview dinner was favored (64.4%) with work restraints being the largest barrier to attendance. Personal days granted for interviews varied by program from zero (16.1%) to greater than 11 (25.0%). Vacation and unpaid leave were utilized by 56.5% and 9.0% respectively. CONCLUSION: Interviewing for fellowship is a burdensome process, but it could be improved by implementing regional coordination, shorter interview days and weekend interview dates. Gathering information from applicants and fellowship directors can help further streamline the process.
Effect of Pregnancy Reasonably Excluded Guide on Pregnancy Testing in Outpatient Gynecologic Surgery [23H]
DeJong, Stephanie R. , Holman, Michelle A., Adela, Cope, Claire, Flanagan, Long, Margaret E. , Ainsworth, Alessandra J.

Mayo Clinic

Obstetrics & Gynecology | May 6, 2017 | Volume: 129 | Issue: 1 | Pages: 88S-88S

10.1097/01.aog.0000514925.75038.ac Get It

INTRODUCTION: The Pregnancy Reasonably Excluded Guide (PREG) questionnaire is based on traditional methods of excluding pregnancy including sterilization, menopause, and the World Health Organization criteria. The PREG has been validated and shows a 99-100% negative predictive value for pregnancy (Selected practice recommendations for contraceptive use, 2013: adapted from the world health organization selected practice recommendations for contraceptive use, 2nd edition. MMWR Recomm Rep 2013; 62:1‒60.). Pregnancy testing in our outpatient surgical settings varied by provider. This study compared utilization of pregnancy tests in the outpatient gynecologic surgery setting after implementation of universal PREG administration. METHODS: All women undergoing outpatient gynecologic surgery were prospectively evaluated between March and September 2016. Administration of the PREG to women 18-49, excluding those undergoing procedures related to pregnancy, was implemented in July and rates of pregnancy testing pre- and post-implementation were compared using Fisher’s exact test. RESULTS: 369 patients underwent an outpatient gynecologic procedure during the study period (excluding a two week washout period after implementation). In the pre-implementation group, 136 met inclusion criteria with 45 pregnancy tests performed (33.1%). After implementation, 80 patients met inclusion criteria and 17 pregnancy tests were performed as indicated by PREG response (21.3%), demonstrating over one third reduction in pregnancy test administration (p = 0.086). No pregnancy tests were positive and no false negative evaluations were identified. Physician and nursing staff requested continued use of the PREG after the trial. CONCLUSION: PREG administration on admission for outpatient gynecologic surgery consistently and effectively identifies patients in whom pregnancy testing improves the value of care.
Elagolix Alone and With Add-Back Decreases Heavy Menstrual Bleeding in Women With Uterine Fibroids [21H]
Stewart, Elizabeth , Owens, Charlotte D., Duan, W. Rachel, Gao, Jingjing , Chwalisż, Kristof , Simon, James A.

Mayo Clinic

Obstetrics & Gynecology | May 6, 2017 | Volume: 129 | Issue: 1 | Pages: 87S-87S

10.1097/01.aog.0000514923.67415.29 Get It

INTRODUCTION: Elagolix, an oral gonadotropin-releasing hormone antagonist, with and without add-back therapy, was evaluated in premenopausal women with heavy menstrual bleeding (HMB; greater than 80 mL/month menstrual blood loss [MBL]) associated with uterine fibroids (UF). METHODS: This double-blind, randomized, placebo-controlled, parallel group study evaluated the efficacy and safety of 6 months of treatment in 2 cohorts, with four arms/cohort: elagolix alone as 300 mg twice daily in cohort 1 (C1) and 600 mg once daily in cohort 2, and in both cohorts, placebo, elagolix with add-back therapy of estradiol (E2)/norethindrone acetate (NETA), low dose 0.5 mg E2/0.1 mg NETA (LDA), or standard dose 1.0 mg E2/0.5 mg NETA (SDA). The primary endpoint was the percentage of women with less than 80 mL MBL assessed by the alkaline-hematin-method and at least 50% reduction in MBL from baseline to the last 28 days of treatment. Adverse events (AE), changes in bone mineral density (BMD) and quality of life (QoL) were assessed. RESULTS: In C1, 259 women were randomized and treated; 80% completed treatment. C1 responses for the primary endpoint were 92% in elagolix alone, 85% elagolix+LDA, 79% elagolix+SDA, and 27% placebo (all p < .001 vs. placebo). Add-back therapy attenuated hot flushes and lumbar spine BMD decreases in a dose-dependent manner; there were no statistically significant differences in BMD between elagolix+SDA and placebo at month 6. All elagolix treatments were associated with improved QoL. Results were similar in C2. CONCLUSION: Elagolix with or without add-back significantly reduced MBL in UF-associated HMB. Hot flushes and BMD decreases were reduced by add-back in a dose-dependent manner.
Prevalence of Abnormal Pap Smear in Women Undergoing Liver Transplantation [15E]
Threadcraft, Marcus , Guha, Paulami, Wells, A. Judson , Dinh, Tri, Nguyen, Justin H. , Harnois, Denise M.

Mayo Clinic

Obstetrics & Gynecology | May 6, 2017 | Volume: 129 | Issue: 1 | Pages: 55S-56S

10.1097/01.aog.0000514806.16797.34 Get It

INTRODUCTION: Female patients being evaluated for liver transplantation (LT) routinely undergo a gynecologic exam including cervical cancer screening. The prevalence of cervical cytologic abnormalities in this high risk population is unknown. Our study determines prevalence of cervical cytologic abnormalities, HPV positive status, and risk factors for abnormal cervical screening for this population. METHODS: With Institutional review board approval, we reviewed 375 charts of women undergoing evaluation for LT from 2008‒2013 at Mayo Clinic Florida. We recorded demographics, Pap smear results, High risk HPV positive results, and co-morbid conditions. Univariate analysis was done to determine risk factors. We compared the result of the LT group to the general female population getting cervical cancer screening during the same time period. RESULTS: 37 of 375 (9.86%) LT patients had abnormal Pap smear, compared to 1784 of 26118 (6.83%) of the general population patients (p < 0.01). Among LT patients with cervical cytologic abnormalities, 40.5% were ASCUS, HPV positive (64.8% for non-LT patients), 29.7% were LSIL (28.1% for non-LT patients), 5.4% were HSIL (6.7% for non-LT patients) and 24.3% were cytology negative with HPV positive (0.2% for non-LT patients, p < 0.05). Younger age and presence of hypertension were associated with higher risk of having an abnormal cervical cytology or positive HPV status among LT patients. CONCLUSION: Patients undergoing evaluation for LT have increased prevalence of abnormal cervical cytology, or a positive High risk HPV test. Gynecologic surveillance for this high risk population is recommended.